Introduction
DNA methylation has been linked to carcinogenesis. Investigation of the events in human cancer has provided key insights into understanding the mechanisms of cancer development (Suzuki and Bird, 2008) . Hypermethylation of human tumor suppressor genes (TSGs) leads to the silencing of genes responsible for tumor suppression, thus causing cancers. Aberrant DNA methylation patterns have been suggested as biomarkers in cancer molecular diagnostics (Laird, 2003) and for the design of new generations of targeted approaches for clinical intervention (Laird, 2003; Suzuki and Bird, 2008) . For example, demethylating agents can be used for the treatments of hypermethylation-associated tumors (Laird, 2003; Issa, 2004; Suzuki and Bird, 2008) . However, the clinical usefulness of methylation is still limited due to the fact that no one technique is broadly accurate for quantification and sensitive detection of methylation changes in cancers (Suzuki and Bird, 2008) . Large-scale studies that enable evaluating quantitative alterations of methylation for multiple CpG sites in various gene regions and testing a large number of samples with automation are rare (Issa, 2004; Suzuki and Bird, 2008 ).
SEQUENOM's EpiTYPER assay created the opportunity for the high-throughput quantitative and semiquantitative analysis of DNA methylation status using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and Mass-CLEAVE reagent, which is based on base-specific (C/T) cleavage reactions (Stanssens et al., 2004; Ehrich et al., 2005) . The robustness of the approach for quantifying methylated and unmethylated DNA has been confirmed earlier by SEQUENOM (Ehrich et al., 2008) and also by our group (Radpour et al., 2008) .
Breast cancer is the most common type of cancer and most common leading cause of cancer death in women. In this study, for the first time, we investigated semiquantitative methylation changes of 22 human genes (APC, BIN1, BMP6, BRCA1, BRCA2, CAD-HERIN 1, CST6, DAPK1, EGFR, ESR2, GSTP1, NES1, Nm23-H1, P16, P21, Progesterone receptor, Prostasin, RAR-b, RASSF1, SRBC, TIMP3 and TP53) in the malignancy using the high-throughput robust system with automation to search for novel biomarkers applicable to the management of patients. The selected candidate cancer genes for this study have annotated functionality in the cell adhesion, cell interaction, invasion, metastasis, angiogenesis or gene expression during cancer development and progression according to the OMIM (Online Mendelian Inheritance in Man database; http://www.ncbi.nlm.nih.gov/omim) (Supplementary Data). A two-way hierarchical cluster analysis was used to identify breast cancer-specific hypermethylated genes according to differences in methylation between cancerous and normal breast tissues on large-scale CpG dinucleotide analysis in the 22 genes. In order to understand the relationship between methylation and transcription events, individual semiquantitative assessment of the methylation status of each CpG dinucleotide was carried out to check the position of hypermethylated CpG sites on the genes.
Results
Sensitive detection of methylation status using high-throughput MALDI-TOF MS with automation The theory, practice and assay concept of the system have been published by the company and our group (Ehrich et al., 2008; Radpour et al., 2008) . The system enables combining quantitative, sensitive, automated and high-throughput detection of methylation status in a single technique.
Quantitative methylation analysis. For every cleaved CpG site, the intensity of a pair of mass signals, one representing methylated and/or another one representing unmethylated DNA, was recorded and interpreted by MassARRAY EpiTYPER software. The relative methylation status was estimated by dividing the peak intensity, or area of the methylated DNA, by the sum of the intensities or areas of the methylated and unmethylated components. The ratios between methylated and unmethylated DNA were obtained as quantity of methylation for further analysis. In our group, we mixed full methylated DNA into the pure unmethylated DNA in different ratios of 100:0, 50:50, 25:75, 5:95 and 0:100. The assay was able to discriminate the methylated and unmethylated components according to the ratios (Radpour et al., 2008) .
Sensitive detection. The assay enabled reliable detection of the methylated DNA in as little as 5 ng of DNA per PCR. At the lowest template input of 2.5 ng, some of the replicates failed to generate detectable fragments with distinctive signal-to-noise ratios in the spectrum (Radpour et al., 2008) .
High-throughput automation. The approach is completely automated for high-throughput analysis of as much as 384 samples running on one silico-chip.
Using paraffin-embedded tissues for methylation analysis A major limitation of using formalin-fixed and paraffinembedded tissue sections is the significant degree of degradation, fragmentation and chemical modification of the nucleic acids recovered from fixed tissues (Srinivasan et al., 2002; Radpour et al., 2008) . In this study, we explored the feasibility of using paraffinembedded tissues for the methylation analysis on MALDI-TOF silico-chips. Before carrying out the methylation analysis, we quantified the yield of extracted DNA from formalin-fixed paraffin-embedded tissues by real-time PCR for GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene. The quality of the DNA allowed permitting successful amplification and quantification of the GAPDH gene in all samples. In our study, the calls and peaks for determining methylated and unmethylated fragments were successfully obtained from the mass spectrometry after the treatments of in vitro transcription and T-cleavage. Figure 1 and Supplementary Data 2). From 23 analysed amplicons in 22 selected genes, 4 amplicons (DAPK1, NES1, Prostasin and RARb) contained CpG-poor islands (with number of CpG sites o20) and others were CpG-rich islands (with number of CpG sites >20) ( Table 1 ). About 43% of CpG sites were defined as having a low degree of methylation with mean methylation levels below 30%, and 27% of CpG sites were defined as having a high degree of methylation with mean methylation levels above 90% (Supplementary Data 2) .
Using the two-way hierarchical cluster analysis, we could find different levels of methylation in 17 genes between cancerous and adjacent normal tissues (Supplementary Data 2). No significant differences of methylation patterns between cancerous and normal tissues could be found in the other five studied genes (BRCA2, EGFR, NM23-H1, Prostasin and TP53) (P>0.05). For these five genes, we could analyse >60% of CpG sites in amplicons (55% in BRCA2, 47% in EGFR, 53% in NM23-H1, 70% in Prostasin and 77% in TP53) ( Table 1) .
Identifying the breast cancer-specific hypermethylated genes From these 17 genes, the top 10 genes with a high degree of methylation across the 96 studied samples and significant different levels of methylation between cancerous and adjacent normal tissues (Po0.05) were selected by distance statistic analysis using pair-wise clustering (Figure 2A (A1) and (A2)). The top 10 hypermethylated genes identified by the distance annotation from the 22 studied genes were APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3 for breast cancer (Figures 2A(A3) and 3).
For the 10 hypermethylated genes, we could detect >61% of CpG sites in amplicons (58% in APC, 60% in BIN1, 70% in BMP6, 57% in BRCA1, 50% in CST6, 47% in ESRb, 78% in GSTP1, 60% in P16, 50% in P21 and 75% in TIMP3) ( Table 1 ). In the 10 hypermethylated genes, 39% of CpG sites were methylated with a low degree (average methylation below 30%) and 32% of CpG sites had mean methylation levels above 90% (Supplementary Data 2). The complete sequence and position of CpG sites that showed differences between cancerous and normal tissues are summarized in Supplementary Data 2.
Semiquantitative methylation profiles of 22 genes in three subgroups of patients Gene clustering of all 22 studied genes was performed independently for each subgroup (invasive ductal carcinoma, infiltrating ductal carcinoma and infiltrating lobular carcinoma) using a two-dimensional hierarchical clustering algorithm ( Figure 2B ). No significant differences of methylation status between these three subgroups were found (P>0.05). Independent distance analysis for the three subgroups of patients confirmed that APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3 can be identified as the top 10 hypermethylated genes in all subgroups ( Figure 2B ). In a study cohort, we had eight patients who were ER-bpositive (Table 2) , and all of these patients had no hypermethylated profile for the estrogen receptor-beta (ESR2) gene.
Comparison of methylation rate with consensus sequences and recognition sites of well-known transcription factors The methylation rate and place of each CpG site were compared with the consensus sequences and recognition sites of well-known transcription factors (upstream sites for regulatory enhancers, CAAT box, GC box, transcription factor IIB recognition elements, TATA box, initiation site of transcription and downstream promoter elements). In comparing the mean methylation value of CpG site positions of all 22 studied genes in the cancerous and normal tissue samples with the consensus sequences, we found that most of the hypermethylated CpG sites for top 10 genes in the cancerous samples were located in a range of À75 to þ 1, including the TATA box, BRE sequence and CAAT box, but in normal samples, the CpG sites were differentially methylated and located randomly in the 5 0 -UTRs (untranslated regions) of the studied genes (Figure 4 ). In the other 12 studied genes, we could not find significant association between place of the CpG sites and conserved sequences.
Discussion
The knowledge of methylation alterations in cancer has been collected for decades. Laird (2003) concluded that 'no one technique or general approach is superior, as the competing goals of quantitative accuracy, sensitive detection, and high local or global informational content, compatibility with formalin fixed tissues and compatibility with automation are not found in a single technique'. In this study, we explored the feasibility of combining accuracy, sensitive detection, high local or global informational content, compatibility with paraffin-embedded tissues and compatibility with automation in a single technique to identify breast cancer-specific DNA methylation changes.
For the first time, we assessed the methylation status of 22 genes in 96 paired normal and cancerous breast tissues from 48 patients (48 breast cancerous tissues and 48 paired normal tissues) using the high-throughput assay on MALDI-TOF MS. Using hierarchical clustering we found that CpG sites from the promoter regions of 17 genes exhibited significantly different methylation degrees (Po0.05) between cancerous and adjacent normal tissues (Figure 1 and Supplementary Data 2). Distance analysis of the methylation differences showed the top 10 genes, such as APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3, selected from 17 significant genes with hypermethylation in breast cancer tissues (Figure 3) . The in silico digestion was performed for the T-cleavage assay. The percentage of informative CpG sites (total sites) in the amplicon is divided into single sites (single CpG sites) and composite sites (two or three adjacent CpG sites fall within one fragment, or when fragment masses are overlapping). N-34 N-36 N-38 N-18 N-35 N-37 N-3 N-4 N-12 N-13 N-14 N-15 N-16 N-17 N-33 N-5 N-6 N-19 N-7 N-8 N-20 N-22 N-23 N-24 N-25 N-26 N-39 N-27 N-28 N-29 N-30 N-45 N-46 N-21 N-31 N-32 N-48 N-40 N-42 N-43 N-41 N-44 N-47 N-9 N- The top 10 hypermethylated genes are involved in cell cycle and DNA repair (BRCA1, P16 and P21), invasion and metastasis (CST6 and TIMP3), cell proliferation (ESRb), signal transduction (APC, BIN1 and BMP6) and cell detoxification (GSTP1). Nine out of the 10 hypermethylated genes act as TSGs, whereas ESRb regulates cell proliferation and functions similar to the TSGs (OMIM database). Hypermethylation of TSGs causes the inactivation of the genes that are important in suppressing the development of most or all tumor types. Eckhardt et al. reported that about one-third of the differentially methylated 5 0 -UTRs are inversely correlated with transcription in normal tissues. In this study, our data showed that hypermethylated CpG sites on the top 10 genes in the cancerous samples were mostly located near the TATA box and BRE sequence (Figure 4 ), but in normal samples the CpG sites were differentially methylated and located randomly in the 5 0 -UTRs, which is similar to the observation in the previous study (Eckhardt et al., 2006) . The methylated CpG sites of the other 12 studied genes were distributed randomly in the 5 0 -UTRs and we could not find significant association between place of the CpG sites and conserved sequences. These data suggest that the hypermethylation may result in transcription alterations of those TSGs. Thus, inhibition of DNA hypermethylation and consequent reactivation of these genes is an attractive avenue for the development of novel therapeutics (Jones and Baylin, 2002; Suzuki and Bird, 2008) . This strategy is particularly appealing because in normal cells, these genes are not normally regulated by DNA methylation. Therefore, the toxicity of DNA methylation inhibitors or DNA demethylation agents to noncancerous tissue could potentially be well below that of cytotoxic anticancer drugs. The targeted therapy should likely be more efficacious and safer for patients. Recently, two studies showed that the methylation process becomes transient, cyclical and dynamic (Kangaspeska et al., 2008; Metivier et al., 2008) . Estrogen and anticancer drugs can cause changes in methylation status in breast cancer cell lines within 10 min (Kangaspeska et al., 2008) . Unlike the stable and unchangeable pathological somatic mutations, the cyclical and dynamic epigenetic nature may be useful for developing new strategies in the treatment of cancer patients, and in risk assessment of cases before the onset, through modification of pathological methylation patterns. To this end, our data identifying the top 10 hypermethylated genes would be important indicators in developing such strategies.
Aberrant DNA methylation patterns can also be used as biomarkers in cancer molecular diagnostics. In our study, the 10 hypermethylated genes enabled distinguishing cancerous breast tissues from normal breast tissues, suggesting that the genes may serve as classification markers for facilitating biopsy/diagnosis and staging and surgical margins in breast cancer management. Lofton-Day et al. (2008) successfully used colorectal cancer tissue-specific methylated DNA as a marker to identify tumor-derived methylated DNA in plasma for developing sensitive and specific blood-based tests applicable in screening and early detection of the disease. Tumor-specific cell-free hypermethylated p16 DNA in the serum of patients with colorectal cancer has shown prognostic value before and during therapy (Zou et al., 2002; Nakayama et al., 2003) . Zhang et al. (2007) observed that hepatocellular carcinoma-specific methylation changes could be detectable in the patients' serum samples up to 9 years before the diagnosis of the condition. These studies suggest that cancer tissuespecific methylation changes can be used in developing blood-based tests for risk assessment, earlier diagnosis and monitoring of cancers. The breast cancer tissuespecific methylation changes identified by our study may provide valuable information for developing bloodbased tests in management of the malignancy.
Technically, we successfully obtained the cancerous and normal breast tissue samples for this study by relative immunohistochemistry staining instead of using microdissection, which requires sophisticated and expensive equipment not applicable to many of diagnostic or research laboratories. Our method for the semiquantitative methylation analysis used in paraffin-embedded samples, which are mostly available to be obtained for subsequent analysis. In this study, we used only a single T-cleavage reaction instead of 2-4 cleavage reactions for assessment of the methylation status. Although the cost for a single cleavage reaction has been obviously reduced, the sensitivity of the modified approach has not been significantly decreased (Radpour et al., 2008) .
In this study, we did not find significant differences in methylation degrees between cancerous and normal tissues (P>0.05) in the promoter regions of five analysed genes (BRCA2, EGFR, NM23-H1, Prostasin and P53) (Supplementary Data 2) . According to previous reports, these genes were involved in breast carcinogenesis, mostly through mutations rather than hypermethylation (Sjoblom et al., 2006; Trent and Touchman, 2007; Wood et al., 2007) .
As DNA methylation changes in human cancer are complicated and vary between the different types of cancer, every novel discovery in the epigenetic landscape and every development of an improved approach for accurate analysis of the events may provide a new Comparison between semiquantitative analysis of methylation for the top 10 hypermethylated genes in the breast cancerous tissues and paired normal tissues. Our data showed the significant differences of methylation patterns between for cancerous and normal tissues (Po0.05).
opportunity for targeted agents and accurate diagnosis in human cancer. We hope that the breast cancer tissuespecific hypermethylated genes identified in this study by the MALDI-TOF MS will provide valuable information in their application for the classification, sensitive detection, risk and therapy assessment of breast cancer, as well as for developing novel targeted therapeutic strategies through modification of pathological epigenetic changes in cancer.
Materials and methods

Samples
The study was approved by the local institutional review board. A total of 96 paraffin-embedded different tissue samples (48 breast cancerous tissues and 48 paired normal tissues) were collected from 48 patients with breast cancer. Paraffin-embedded sections were examined by two experienced pathologists. None of the studied cases have a hereditary form of breast cancer. The criteria for checking hereditary patients were germline mutations in BRCA1 or BRCA2, and in primary invasive breast carcinoma. According to the pathological tumor status and immunohistochemistry staining, we classified our patients in three subgroups (invasive ductal carcinoma, infiltrating ductal carcinoma and infiltrating lobular carcinoma). Table 2 and 3 summarize the clinical data of patients and their response to the screening receptors/markers. DNA extraction was performed from 3-5 sections of each 10-mm-thick paraffin-embedded sample (around 0.01-0.02 g of tissue), using the High Pure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany).
Bisulfite treatment
The EZ-96 DNA Methylation Kit (Zymo Research, Orange, CA, USA) was used for bisulfite conversion of the target sequences. The C/T conversion reaction was performed using the PCR program as follows: 95 1C for 30 s and 50 1C for 15 min, which was repeated for 46 cycles.
Primer design and PCR tagging for EpiTYPER assay
We designed primers for the 22 genes to cover the regions with the most CpG sites. Our selected amplicons were mostly located in the promoter region of genes or started from the promoter and ended in the first exon. For three specific genes (ESR-b, PGR and TIMP3), the amplicons that contained CpG sites were located in the first exon and there were no CpG sites in the promoter region. The primers were designed using MethPrimer (San Francisco, CA, USA) (Li and Dahiya, 2002) . In PCR amplification, a T7-promoter tag was added to the reverse primer and a 10mer-tag sequence was added to the Invasive ductal carcinoma  8  15  6  17  13  10  2  21  0  23  7  16  Infiltrating ductal carcinoma  4  12  2  14  5  11  1  15  0  16  3  13  Infiltrating lobular carcinoma  2  7  0  9  2  7  0  9  0  9 1 8 Figure 4 Comparison of the methylation rate and place of CpG sites according to the sequences and recognition sites of the transcription factors in the 22 studied genes for 48 cancerous and 48 normal tissue samples.
forward primer to balance the PCR primer length. The primer sequences, annealing temperatures (T a ) and PCR conditions are described in Supplementary Data 1.
In vitro transcription and T-cleavage assay Unincorporated dNTPs were dephosphorylated by adding 1.7 ml H 2 O and 0.3 U shrimp alkaline phosphatase (SEQUE-NOM, San Diego, CA, USA). The reaction was incubated at 37 1C for 20 min and shrimp alkaline phosphatase was then heat inactivated at 85 1C for 10 min. Typically, 2 ml of the PCR were directly used as a template in a 5-ml transcription reaction. T7 R&DNA Polymerase (20 U) (Epicentre, Madison, WI, USA) was used to incorporate dTTP in the transcripts. Ribonucleotides were used at 1 mmol/l and the dNTP substrate at 2.5 mmol/l. In the same step, the RNase-A enzyme (SEQUENOM) was added to cleave the in vitro transcripts (T-cleavage assay). The mixture was further diluted with H 2 O to a final volume of 27 ml. Conditioning of the phosphate backbone was achieved by adding 6 mg of Clean Resin (SEQUENOM) before performing MALDI-TOF MS.
Mass spectrometry
After robotically dispensing 22 nl of cleavage reaction onto silicon matrix preloaded chips (SpectroCHIP; SEQUENOM), the mass spectra were collected using a MassARRAY Compact MALDI-TOF (SEQUENOM) and spectra's methylation ratios were generated by the EpiTYPER software v1.0 (SEQUENOM).
Statistical methods
Relative methylation was compared between cancerous and paired normal tissues using the Wilcoxon signed-rank test, a nonparametric counterpart of the paired t-test. The one-way analysis of variance test was used to compare relative methylation between three subgroups. Using the two-way hierarchical cluster analysis, the most variable CpG fragments for each gene were clustered based on pair-wise Euclidean distances and linkage algorithm for all of the 96 tissue samples (48 cancerous tissues and 48 paired normal tissues), according to the previously developed method (Radpour et al., 2008) . The gene clustering was performed independently using a hierarchical clustering algorithm. For gene clustering, pairwise similarity metrics were calculated for each gene separately on the basis of methylation ratio of cancerous tissues across the adjacent paired normal tissues. The procedure was performed using the double dendrogram function of the Gene Expression Statistical System for Microarrays (GESS, version 7.1.13; NCSS, Kaysville, UT, USA).
Additional information
The sequence of PCR-tagged primers for in vitro transcription and PCR conditions are available in Supplementary Data 1.
The complete data for high-throughput methylation analysis of informative CpG sites in 22 breast cancer-related genes, including gene location, amplicon size and place of CpG sites in the amplicon and two-way hierarchical cluster analysis of 48 cancerous breast tissues and 48 normal breast tissues are available in Supplementary Data 2. Infiltrating lobular carcinoma 9 5 0 ± 10.9 (32-65) 5 4 3.25 ± 1.6 (1.5-6) 5 1 2 4 3
Abbreviations: L, left; R, right.
